Home ›
News ›
Lipoxen Additional listing
Lipoxen Additional listing
10 November 2009
London, UK, 10 November 2009 - Lipoxen PLC (AIM:LPX) a
bio-pharmaceutical company specialising in the development of high
value differentiated biologicals, vaccines and siRNA delivery,
announces that application has been made to AIM, a market of the
London Stock Exchange plc, for the admission of 187,145 ordinary
shares of 0.5p each (the "New Ordinary Shares").
The New Ordinary Shares are being admitted pursuant to the
exercise of options under the Lipoxen Plc Unapproved Share Option
Plan.
It is expected that dealings in the New Ordinary Shares, which
will rank pari passu in all respects with the existing issued share
capital of the Company, will commence on 11 November 2009.
Enquiries:
|
Lipoxen plc
|
+44 (0)20 7691 3583
|
|
M. Scott Maguire, Chief Executive Officer
|
|
|
|
|
|
Singer Capital Markets (nominated adviser)
|
+44 (0)20 3205 7500
|
|
Jeff Keating / Claes Spång
|
|
|
|
|
|
Noble & Company
|
+44 (0) 20 7763 2200
|
|
John Llewellyn-Lloyd / Sam Reynolds
|
|
|
|
|
|
Buchanan Communications
|
+44 (0)20 7466 5000
|
|
Lisa Baderoon, Rebecca Skye Dietrich, Catherine Breen
|
|